Artículos de revistas
Comparative Study Of The Efficacy And Safety Of Valdecoxib And Piroxicam In The Treatment Of Patients With Primary Dysmenorrhea [comparação Da Eficácia E Segurança De Valdecoxibe* E Piroxicam No Tratamento Da Dismenorréia Primária]
Registro en:
Revista Brasileira De Medicina. , v. 64, n. 7, p. 318 - 322, 2007.
347264
2-s2.0-34547750491
Autor
Barbosa I.C.
Fernandes C.E.
Isaia Filho C.
Tadini V.
Camargos A.F.
Finotti M.C.C.F.
Petracco A.
De Oliveira H.C.
Bagnoli V.R.
Peixoto R.M.L.
Institución
Resumen
Introduction: Dysmenorrhea is described as a moderate or severe pain experienced during or immediately before menstruation and it can cause an alteration of women daily activities. Objective: To compare the efficacy and safety of valdecoxib, piroxicam, or placebo in the treatment of patients with primary dysmenorrhea. Methods: A total of 169 subjects were included in this multicenter, double blind, randomized study, to evaluate comparative of efficacy and safety of valdecoxib (Group 1) 40 mg bis a day (first day), and 40 mg once a day for two days in the first menstrual cycle and piroxicam 40 mg once a day for three days another cycle, versus piroxicam (Group 2) 40 mg once day for three days on the first menstrual cycle and valdecoxib 40 mg twice on the first day and once for two days another cycle. Both the groups were compared with placebo group, for two cycles. The efficacy was evaluated by pain relief calculated as the summed weighted pain relief scores to 8 hours (TOTPAR 8h). The SPID 8h, percent of subjects who took rescue medication and percent of subjects who took the second dose of study medication were used to mesure the secondary efficacy. Safety was assessed by adverse events reported by patients of the groups. Results and conclusions: The results of this study showed that valdecoxib is as effective as piroxicam to treat severe pain in women with primary dysmenorrhea. The safety profile of the two drugs was similar, and no serious adverse events was recorded during the study. © Copyright Moreira Jr. Editora. 64 7 318 322 Dawood, M.Y., Primary dysmenorrhea: Advances in pathogenesis and management (2006) Obstet Gynecol, 108, pp. 428-441 Rosenwaks, Z., Seegar-Jones, G., Menstrual pain: Its origin and pathogenesis (1980) J Reprod Med, 25, pp. 207-212 Zhang, W.Y., Li Wan, P.A., Efficacy of minor analgesics in primary dysmenorrhoea: A systematic review (1998) Br J Obstet Gynaecol, 105, pp. 780-789 Milsom, I., Minic, M., Dawood, M.Y., Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: A pooled analysis of five studies (2002) Clin Ther, 24, pp. 1384-1400 Daniels SE, Talwalker S, Torri S, Snabes MC, Recker DP, Verburg KM. Valdecoxibe, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 2002 100: 350-8Korolkovas, A., (2002) Dicionário terapêutico Guanabara 2002/2003, pp. 21.1-21.10. , Rio de Janeiro: Guanabara Koogan Daniels, S.E., Torri, S., Desjardins, P.J., Valdecoxibe for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen (2005) J Gen Intern Med, 20, pp. 62-67 Zhang, Y., Isakson, P., Rathmell, J., Panchal, S., Seiber, K., Distribution of the COX-2 specific inhibitor Valdecoxibe into cerebrospinal fluid following oral administration (2003) J Pain, 4, pp. A765 Zhang, Y., Isakson, P., Rathmell, J., Panchal, S., Seibert, K., Reduction of hyperalgesia, PGE2 in paw exudates, and PGE2 in CSF after oral administration of valdecoxibe or ketorolac (2003) J Pain, 4, pp. A794 Bartfai, T., Telling the brain about pain (2001) Nature, 410, pp. 425-427 Singh, G., Rosen Ramey, D., NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System (1998) J Rheumatol Suppl, 51, pp. 8-16 Strom, B.L., Berlin, J.A., Kinman, J.L., Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study (1996) JAMA, 275, pp. 376-382